Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and Waiver under 18 U.S.C. §208(b)(3) and 21 U.S.C. §355(n)(4)

John Ellis, M.D.

Committee: Cardiovascular and Renal Drugs Advisory Committee

Meeting Date: September 21, 2006

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to discussion of clinical data for aprotinin injection (trade name, Trasylol), an approved product, New Drug Application 020-304, sponsored by Bayer Pharmaceuticals Corporation, a part of Bayer HealthCare AG, a subsidiary of Bayer AG, with the indication for prophylactic use to reduce perioperative blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass in the course of coronary artery bypass graft (CABG) surgery, I am eligible to receive waivers under 18 U.S.C. §208(b)(3) and 21 U.S.C. §355(n)(4).

Type of Interest	Nature	Magnitude
Unrelated Teaching	Competitor	Less than $5,001
Stock	Competitor	Less than $5,001

I hereby request that FDA make this information publicly available on my behalf at the start of the advisory committee meeting for which it is issued. The public disclosure will be accomplished by reading the statement into the record and by making a written copy publicly available at the time of the meeting. I understand that without public disclosure of these interests, the waivers are not valid.

/S/
Signature of SGE

8/15/06
Date